Inteliphage — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Inteliphage is a private, pre-revenue biotech company developing a comprehensive platform to make personalized bacteriophage therapy a practical clinical reality. Its core offering is the PhageXpert™ system, an automated phage susceptibility (phagogram) workflow designed to rapidly match therapeutic phages from its curated library to a patient's specific bacterial infection. By addressing the critical logistical and diagnostic bottlenecks in phage therapy, Inteliphage aims to position itself as a key enabler in the fight against antibiotic-resistant infections, particularly those caused by ESKAPE pathogens.

Infectious DiseasesAntimicrobial Resistance

Technology Platform

Integrated platform for personalized bacteriophage therapy, featuring the PhageXpert™ automated phage susceptibility testing workflow (kit + software) and a curated library of therapeutic bacteriophages.

Opportunities

The massive and growing global burden of antimicrobial resistance (AMR) creates a urgent need for novel solutions like phage therapy.

Inteliphage's platform approach addresses critical bottlenecks in phage therapy adoption, positioning it to become an essential enabler for hospitals.

Evolving regulatory frameworks and increased public funding for AMR solutions in Europe provide a favorable tailwind.

Risk Factors

The regulatory pathway for personalized phage diagnostics and therapeutics is complex and not fully defined.

Achieving widespread hospital adoption requires changing clinical practice and overcoming logistical hurdles.

The company is pre-revenue and faces significant competition from other biotechs and potential entrants from big pharma and diagnostics.

Competitive Landscape

The competitive landscape includes pure-play phage therapy companies (e.g., Adaptive Phage Therapeutics, Locus Biosciences), large diagnostics firms that could develop similar testing, and academic hospital centers with in-house phage programs. Inteliphage differentiates by focusing on the integrated diagnostic-to-therapy workflow rather than a single therapeutic cocktail.

More companies in Biologics / Biosimilars →More companies in Belgium →